Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE Meeting Abstract
| Authors: | Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; Saad, M.; Gurney, H. P.; Jung, W.; Mason, G. E.; Dibaj, S.; Wu, D.; Diorio, B.; Lopez-Gitlitz, A.; Kim, W.; Olmos, D. |
| Abstract Title: | Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1326 |
| Language: | English |
| ACCESSION: | WOS:001087480203573 |
| DOI: | 10.1016/j.annonc.2023.10.087 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA85 -- Source: Wos |
